Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$115.6 million.

  • Tarsus Pharmaceuticals' Net Income towards Common Stockholders rose 46.00% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 38.99%. This contributed to the annual value of -$115.6 million for FY2024, which is 14.97% up from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' Net Income towards Common Stockholders is -$115.6 million, which was up 14.97% from -$135.9 million recorded in FY2023.
  • Tarsus Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$13.8 million during FY2021, with a 5-year trough of -$135.9 million in FY2023.
  • For the 3-year period, Tarsus Pharmaceuticals' Net Income towards Common Stockholders averaged around -$104.5 million, with its median value being -$115.6 million (2024).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 48.43% in 2021, and later plummeted by 349.06% in 2022.
  • Yearly analysis of 5 years shows Tarsus Pharmaceuticals' Net Income towards Common Stockholders stood at -$26.8 million in 2020, then skyrocketed by 48.43% to -$13.8 million in 2021, then plummeted by 349.06% to -$62.1 million in 2022, then crashed by 118.86% to -$135.9 million in 2023, then grew by 14.97% to -$115.6 million in 2024.